Topics:

Weak Provenge sales send Dendreon shares tumbling

August 15, 2013 | By
Tools

Dendreon ($DNDN) had its biggest share price fall in 21 months last week after sales of prostate cancer vaccine Provenge fell short of expectations. The miss means Dendreon now expects to fail to achieve its modest goal of growing sales this year. Article

Filed Under
,

Comments

Press Releases
  • Genetic Technologies Limited (GTG.AX) Announces Appointment Of Chief Financial Officer
  • Hemostemix Names Dr. Rahul Sarugaser As Vice President Of Business And Corporate Development
  • Agenus (AGEN) Appoints C. Evan Ballantyne As Chief Financial Officer
  • Plasticell Appoints Dr Aaron T. T. Chuang As Chief Scientific Officer.
  • Rajiv Shah, M.D., Appointed To Omeros Corporation (OMER)' Board Of Directors
  • More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.